share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/19 20:07

Moomoo AI 已提取核心信息

FOXO Technologies reported Q2 2024 revenues of $28,000, up 133% year-over-year, primarily driven by the acquisition of Myrtle Recovery Centers on June 14, 2024. Net loss improved to $2.16 million compared to $11.29 million in Q2 2023, reflecting lower operating expenses and reduced non-operating charges. The company ended the quarter with $33,000 in cash.The company has restructured into two segments: Healthcare, comprising the newly acquired Myrtle behavioral health services, and Labs and Life, focusing on epigenetic biomarker technology. Operating expenses decreased 79% to $1.62 million, driven by lower employee costs, reduced consulting fees, and the completion of certain research projects.Management secured additional financing through various debt instruments and entered agreements to acquire RCHI's Big South Fork Medical Center. However, FOXO faces significant liquidity challenges, including defaulted Senior PIK Notes and NYSE American listing compliance issues. The company believes it can fund operations through December 2024 if the RCHI acquisition closes but requires additional capital to ensure long-term viability.
FOXO Technologies reported Q2 2024 revenues of $28,000, up 133% year-over-year, primarily driven by the acquisition of Myrtle Recovery Centers on June 14, 2024. Net loss improved to $2.16 million compared to $11.29 million in Q2 2023, reflecting lower operating expenses and reduced non-operating charges. The company ended the quarter with $33,000 in cash.The company has restructured into two segments: Healthcare, comprising the newly acquired Myrtle behavioral health services, and Labs and Life, focusing on epigenetic biomarker technology. Operating expenses decreased 79% to $1.62 million, driven by lower employee costs, reduced consulting fees, and the completion of certain research projects.Management secured additional financing through various debt instruments and entered agreements to acquire RCHI's Big South Fork Medical Center. However, FOXO faces significant liquidity challenges, including defaulted Senior PIK Notes and NYSE American listing compliance issues. The company believes it can fund operations through December 2024 if the RCHI acquisition closes but requires additional capital to ensure long-term viability.
FOXO科技报告称2024年第二季度收入为$28,000，同比增长133%，主要受到2024年6月14日收购Myrtle Recovery Centers的推动。净亏损改善至$216万，相较于2023年第二季度的$1129万，反映出营业费用降低和非营业费用减少。公司在季度末现金余额为$33,000。公司已重组为两个部门：医疗保健部门，包括新收购的Myrtle行为健康服务，以及实验室与生命部门，专注于表观遗传生物标志物科技。营业费用下降79%，至$162万，主要由于员工成本降低、咨询费用减少和某些研究项目的完成。管理层通过多种债务工具获得了额外融资，并签署了收购RCHI的Big South Fork医疗中心的协议。然而，FOXO面临严重的流动性挑战，包括违约的高级PIK票据和纽交所美国上市合规问题。公司相信如果RCHI收购成功，可以在2024年12月之前维持运营，但需要额外资金以确保长期可行性。
FOXO科技报告称2024年第二季度收入为$28,000，同比增长133%，主要受到2024年6月14日收购Myrtle Recovery Centers的推动。净亏损改善至$216万，相较于2023年第二季度的$1129万，反映出营业费用降低和非营业费用减少。公司在季度末现金余额为$33,000。公司已重组为两个部门：医疗保健部门，包括新收购的Myrtle行为健康服务，以及实验室与生命部门，专注于表观遗传生物标志物科技。营业费用下降79%，至$162万，主要由于员工成本降低、咨询费用减少和某些研究项目的完成。管理层通过多种债务工具获得了额外融资，并签署了收购RCHI的Big South Fork医疗中心的协议。然而，FOXO面临严重的流动性挑战，包括违约的高级PIK票据和纽交所美国上市合规问题。公司相信如果RCHI收购成功，可以在2024年12月之前维持运营，但需要额外资金以确保长期可行性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    MSP Recovery
    MSPR
    -- 1.510
    BullFrog AI
    BFRG
    -- 2.080
    CareCloud
    CCLD
    -- 1.610
    OptimizeRx
    OPRX
    -- 9.470
    Claritev
    CTEV
    -- 22.010
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点